Paraneoplastic neurological syndrome (PNS) is uncommon and not well known. PNS can reveal cancer, but its role in seminomas has not been described explicitly. We report the case of a 36-year-old man with unremarkable medical history and no comorbidities who was diagnosed with a retroperitoneal metastatic seminoma. The patient’s general condition deteriorated, and he developed progressive neurological palsy without other clinical anomalies. Electromyography revealed demyelinating, non-lengthy neuropathy. Guillain-Barré syndrome was initially suspected. However, a positron emission tomography scan revealed a retroperitoneal mass, and blood markers revealed increased human chorionic gonadotropin. The patient was diagnosed with PNS, and a computed tomography-guided biopsy revealed a metastatic seminoma without a primary tumor. No circulating neural antibodies were detected. Human polyvalent immunoglobulin was simultaneously administered with chemotherapy. After three cycles of a cisplatin-etoposide-bleomycin, a complete biological and metabolic response rate was observed, and his neurological symptoms rapidly improved. Four years later, the patient responded completely, without any neurological complaints. Paraneoplastic demyelinating inflammatory neuropathy can lead to advanced seminoma diagnosis. Prompt management of seminomas with cisplatin-based regimens provides the best chance of cure for both advanced seminoma and paraneoplastic syndrome.

1.
Oldenburg
J
,
Fosså
SD
,
Nuver
J
,
Heidenreich
A
,
Schmoll
HJ
,
Bokemeyer
C
,
Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2013
;
24
(
Suppl 6
):
vi125
32
.
2.
Bray
F
,
Richiardi
L
,
Ekbom
A
,
Pukkala
E
,
Cuninkova
M
,
Møller
H
.
Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality
.
Int J Cancer
.
2006
;
118
(
12
):
3099
111
. .
3.
Braik
T
,
Evans
AT
,
Telfer
M
,
McDunn
S
.
Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review
.
Am J Med Sci
.
2010
;
340
(
4
):
301
8
. .
4.
Pelosof
LC
,
Gerber
DE
.
Paraneoplastic syndromes: an approach to diagnosis and treatment
.
Mayo Clin Proc
.
2010
;
85
(
9
):
838
54
. .
5.
Muppidi
S
,
Vernino
S
.
Paraneoplastic neuropathies
.
Continuum
.
2014
;
20
(
5
):
1359
72
. Peripheral nervous system disorders. .
6.
Rudnicki
SA
,
Dalmau
J
.
Paraneoplastic syndromes of the peripheral nerves
.
Curr Opin Neurol
.
2005
;
18
(
5
):
598
603
. .
7.
Briani
C
,
Vitaliani
R
,
Grisold
W
,
Honnorat
J
,
Graus
F
,
Antoine
JC
,
Spectrum of paraneoplastic disease associated with lymphoma
.
Neurology
.
2011
;
76
(
8
):
705
10
.
8.
Greenspan
BN
,
Felice
KJ
.
Chronic inflammatory demyelinating polyneuropathy (CIDP) associated with seminoma
.
Eur Neurol
.
1998
;
39
(
1
):
57
8
. .
9.
Gabriel
CM
,
Gregson
NA
,
Hughes
RAC
.
Sensory neuropathy and anti-Hu antibodies in a patient with seminoma
.
Eur J Neurol
.
1996
;
3
(
5
):
471
4
. .
10.
Littler
WA
.
Peripheral sensorimotor neuropathy in association with a seminoma of an undescended testicle
.
Postgrad Med J
.
1970
;
46
(
533
):
166
7
. .
11.
Evans
CC
,
Kaufman
HD
.
Unusual presentation of seminoma of the testis
.
Br J Surg
.
1971
;
58
(
9
):
703
4
. .
12.
Voltz
R
.
Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy
.
Lancet Neurol
.
2002
;
1
(
5
):
294
305
. .
13.
de Beukelaar
JW
,
Sillevis Smitt
PA
.
Managing paraneoplastic neurological disorders
.
Oncologist
.
2006
;
11
(
3
):
292
305
. .
14.
Antoine
JC
,
Camdessanché
JP
.
Paraneoplastic neuropathies
.
Curr Opin Neurol
.
2017
;
30
(
5
):
513
20
. .
15.
Kimura
M
,
Onozawa
M
,
Fujisaki
A
,
Arakawa
T
,
Takeda
K
,
Dalmau
J
,
Anti-Ma2 paraneoplastic encephalitis associated with testicular germ cell tumor treated by carboplatin, etoposide and bleomycin
.
Int J Urol
.
2008
;
15
(
10
):
942
3
.
16.
Mandel-Brehm
C
,
Dubey
D
,
Kryzer
TJ
,
O’Donovan
BD
,
Tran
B
,
Vazquez
SE
,
Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis
.
N Engl J Med
.
2019
;
381
(
1
):
47
54
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.